In this interview, Lumos’ CFO Barrie Lambert discusses Lumos’ upcoming paediatric study designed to expand FebriDx® access to younger patients, our recent CLIA waiver submission which, if approved, will open access to more than 270,000 clinics and 80 million annual patient visits in the United States, and our ongoing collaboration with Hologic, one of the world’s leading diagnostic companies.